Previous 10 | Next 10 |
2023-10-26 19:25:31 ET Alimera Sciences, Inc. (ALIM) Q3 2023 Results Conference Call October 26, 2023 09:00 AM ET Company Participants Scott Gordon - CORE IR Rick Eiswirth - President, CEO & Director Russell Skibsted - SVP & CFO Conference Call Part...
2023-10-26 07:17:56 ET More on Alimera Sciences Alimera Sciences, Inc. (ALIM) Q2 2023 Earnings Call Transcript Alimera Sciences Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Alimera Sciences Historical earnings data for Alimera Sciences ...
CenterPoint Energy Inc (Holding Co) (CNP) is expected to report $0.37 for Q3 2023 The Hershey Company (HSY) is expected to report $2.47 for Q3 2023 ASE Technology Holding Co. Ltd. American Depositary Shares (each representing Two) (ASX) is expected to report for Q3 2023 Reliance Steel...
Net Revenue up 72% to $23.4 Million vs. Q3 2022 Net Loss Decreased by 74% to $1.4 Million vs. Q3 2022 Adjusted EBITDA of $5.4 Million in Q3 2023 Successful Integration of YUTIQ into the U.S. Segment ATLANTA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. ...
Alimera Sciences Inc. (ALIM) is expected to report $-0.41 for Q3 2023
2023-10-25 13:23:27 ET More on Alimera Sciences Alimera Sciences, Inc. (ALIM) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Alimera Sciences Historical earnings data for Alimera Sciences Financial information for Alimera Sciences ...
ATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will repor...
ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that cli...
2023-10-03 08:17:00 ET More on Alimera Sciences Alimera Sciences, Inc. (ALIM) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Alimera Sciences Historical earnings data for Alimera Sciences Financial information for Alimera Sciences ...
ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced t...
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
2024-07-07 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 11:30:02 ET Alliance Global Partners analyst issues NEUTRAL recommendation for ALIM on June 25, 2024 10:23AM ET. The previous analyst recommendation was Buy. ALIM was trading at $5.53 at issue of the analyst recommendation. The overall analyst consensus : HOLD...
2024-06-25 07:00:05 ET Yi Chen from H.C. Wainwright issued a price target of $6.00 for ALIM on 2024-06-25 06:08:00. The adjusted price target was set to $6.00. At the time of the announcement, ALIM was trading at $5.54. The overall price target consensus is at $7.25 with...